Glaukos Corporation (GKOS)
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
Glaukos: The Second J-Code Rewrites The Risk Math
Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by iDose TR and the Epioxa launch, with non-GAAP gross margin reaching 85% and breakeven P&L. Management raised 2026 net sales guidance to $680–700M, with iDose TR sales expected at $275–280M and corneal health growth of 20%+.
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up
GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.
Glaukos Q2 Earnings Call Highlights
Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management's expectations.
Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.24 per share a year ago.
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?
GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.
